Reduced ejection fraction co-occurrent and due to chronic heart failure

This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and even death.
The study drug, vericiguat, is already approved for doctors to prescribe to people with worsening of heart failure with chronic HFrEF in India.
Vericiguat increases the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels, allowing more blood to flow through. As a result, the heart is able to pump better.
The participants in this study are already receiving treatment with vericiguat as part of their regular care from their doctors. There is currently limited real-world data on the use of vericiguat. Furthermore, discussing whether vericiguat treatment should start early in people with heart failure can help doctors manage these people better.
The main purpose of this study is to collect information about how well vericiguat works and how safe it is in Indian people with chronic HFrEF who have experienced worsening heart failure. To do this, researchers will collect the following information:
* participants' characteristics, including age, sex, height, weight, and medical history
* additional medicines participants have taken with vericiguat
* other treatment options participants have taken for the treatment of heart failure
* levels of NT-pro BNP* in participants' blood at least one month before taking vericiguat (*NT-proBNP is made by heart muscles. People with heart diseases have increased levels of NT-proBNP in their blood. Measuring NT-proBNP levels in the blood can help doctors identify heart disease.)
* number of participants from India, divided into four zones-North, South, East, and West
* categorization of participants based on how heart failure limits physical activity and classification of heart failure by cause
* change in heart function measured by how much blood the left side of the heart can pump out
* number of hospitalizations and number of participants who died due to heart-related and non-heart-related events
* number of participants who experienced low blood pressure or fainting after starting treatment with vericiguat
* participants who discontinued treatment with vericiguat, due to low blood pressure or fainting
The data will come from the participants' hospital, medical and electronic healthcare records. Data collected will be from Indian people with chronic HFrEF who started taking vericiguat between September 2022 and August 2023.
Researchers will track participants' data and will follow them until Feb 2024. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂沙库巴曲缬沙坦钠片（规格：以沙库巴曲缬沙坦计 100mg（沙库巴曲 49mg/缬沙坦1mg），苏州中化药品工业有限公司生产）与参比制剂沙库巴曲缬沙坦钠片（诺欣妥®，规格：以沙库巴曲缬沙坦计 100mg（沙库巴曲49mg/缬沙坦51mg），Novartis Farma S.p.A.生产, Novartis Pharma SchweizAG 持证）在健康成年受试者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：空腹和餐后状态下，研究单次口服受试制剂沙库巴曲缬沙坦钠片和参比制剂沙库巴曲缬沙坦钠片在健康成年受试者中的安全性。

考察单次口服（空腹/餐后）受试制剂沙库巴曲缬沙坦钠片【规格：以沙库巴曲缬沙坦计200 mg（沙库巴曲97 mg/缬沙坦103 mg）】与参比制剂【商品名：诺欣妥，规格：以沙库巴曲缬沙坦计200 mg（沙库巴曲97 mg/缬沙坦103 mg）】在中国成年健康受试者中的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性，为该药的申报及临床用药提供参考依据。 次要目的： 评价单次单剂量口服1片受试制剂和参比制剂（空腹/餐后）在中国健康受试者中的安全性。